What it is
Diclofenac is an NSAID from the arylacetic acid group, available in many forms: oral (tablets, fast-release soft capsules), topical (gel, patch) and injectable.
In Spain, oral diclofenac requires a prescription. The topical gel is available without a prescription. It is one of the most potent NSAIDs in its class, with greater COX-2 preference than ibuprofen, although it is not as selective as celecoxib.
Preferential COX-2 inhibition with less COX-1 effect
Diclofenac has a somewhat different COX inhibition profile from ibuprofen:
- It inhibits COX-1 and COX-2, but with a greater preference for COX-2 than ibuprofen.
- Less COX-1 inhibition → in theory, lower gastric risk than other NSAIDs at equivalent doses.
- However, clinical studies show gastrointestinal risk similar to or greater than ibuprofen in practice.
- Higher cardiovascular risk than ibuprofen and naproxen: similar to that of the selective COX-2 inhibitors.
- The topical form acts locally with minimal systemic absorption: a much better safety profile.
At the counter
When to recommend it
- Topical gel (no prescription): localised muscle pain, bruises, sprains, tendinitis, joint pain
- The topical form is the first option when pain is localised: comparable efficacy to the oral form with minimal systemic effects
- Oral (on prescription): moderate to severe joint pain, dysmenorrhoea, post-operative pain
- In inflammatory pain where ibuprofen has not been enough
When not to
- Oral without a prescription: in Spain it requires one
- History of cardiovascular disease (heart attack, stroke): it increases cardiovascular risk
- Moderate to severe heart failure
- Pregnancy (avoid from week 20; contraindicated in the third trimester) and breastfeeding
- Moderate to severe kidney failure
- Do not combine with other NSAIDs or with anticoagulants without medical supervision
Warnings
- Important CARDIOVASCULAR RISK: oral diclofenac has the highest cardiovascular risk of the commonly used NSAIDs, comparable to the selective COX-2 inhibitors. Avoid in patients with established cardiovascular disease.
- Caution LIVER TOXICITY: diclofenac carries a higher risk of liver toxicity than other NSAIDs. Raised liver enzymes and even fulminant hepatitis (rare but serious) have been described. Avoid in liver disease.
- Caution INTERACTION WITH LITHIUM: diclofenac reduces the renal excretion of lithium and can cause lithium toxicity.
- Caution TOPICAL GEL: although systemic absorption is low, over large areas or under occlusion it can be significant. Do not apply to broken skin or mucous membranes.
- Worth knowing PHOTOSENSITIVITY: topical use can increase the sun sensitivity of the treated area. Protect it from the sun after applying the gel.
Pharmacokinetics
- Absorption
- Oral: rapid and complete absorption (almost 100%), but intense hepatic first-pass metabolism → bioavailability of 50–60%. Fast-release soft capsules act sooner. Peak plasma level: 1–2 hours.
- Distribution
- High plasma protein binding (>99%). It distributes well into inflamed tissues, synovial fluid (useful in arthritis) and muscle.
- Metabolism
- Intense hepatic metabolism by CYP2C9 (mainly) and CYP3A4. It produces several metabolites, some active. Caution with CYP2C9 inhibitors.
- Elimination
- Renal (65%) and biliary (35%). Half-life: 1–2 hours. Duration of clinical effect: 6–8 hours (standard formulations) or 12–24 hours (prolonged release).
Topical diclofenac vs oral diclofenac
| Aspect | Topical diclofenac | Oral diclofenac |
|---|---|---|
| Systemic absorption | Very low (3–10% of the dose) | High (~50–60% after first pass) |
| Local concentration | Very high in subcutaneous tissues | Depends on systemic distribution |
| Gastric risk | Minimal | Moderate |
| Cardiovascular risk | Minimal | Increased |
| Indication | Localised musculoskeletal pain | Moderate to severe widespread or joint pain |
| Available without prescription | Yes (gel in Spain) | No (prescription required) |
For localised pain, the topical gel is the first choice: just as effective in the area, with a tiny fraction of the systemic risks. The oral form is kept for more widespread pain or when the topical route is not enough.
Self-assessment
Three questions. When you check your answers you will see the explanation for each one.
-
Oral diclofenac has the highest cardiovascular risk of the commonly used NSAIDs and is particularly inadvisable in patients with established cardiovascular disease. The topical gel is an alternative with minimal systemic absorption and much lower cardiovascular risk for localised pain such as knee pain.
-
The topical route achieves concentrations in the target tissue (muscle, tendon, superficial joint) much higher than those reached orally, with systemic absorption of only 3–10% of the dose. This translates into comparable local efficacy with minimal gastric and cardiovascular risk.
-
Prostacyclin (PGI2), produced by endothelial COX-2, is a vasodilator and inhibits platelets. Thromboxane A2 (TXA2), produced by platelet COX-1, is a vasoconstrictor and promotes clotting. More COX-2-selective inhibitors reduce prostacyclin more without reducing TXA2 proportionally, shifting the balance towards thrombosis and vasoconstriction.
Training content. It does not replace the summary of product characteristics or clinical judgement.